Navigation Links
Questcor Pharmaceuticals Expands Repurchase Program
Date:5/16/2012

Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "estimates," "expects," "growth," "may," "plans," "potential," "should," "substantial" or "will" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

  • Our reliance on Acthar for substantially all of our net sales and profits;
  • Reductions in vials used per prescription resulting from changes in treatment regimens by physicians or patient compliance with physician recommendations;
  • Our ability to continue to generate revenue from sales of Acthar to treat on-label indications associated with NS, and our ability to develop other therapeutic uses for Acthar;
  • Our ability to receive high reimbursement levels from third party payers;
  • An increase in the proportion of our Acthar unit sales comprised of Medicaid-eligible patients and government entities;
  • Our ability to effectively manage our growth, including the expansion of our NS selling effort, and our reliance on key personnel;
  • Volatility in Questcor's monthly and quarterly Acthar shipments, estimated channel inventory, and end-user demand, as well as volatility in our stock price; and
  • Other risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2011 as filed with the Securities and Exchange Commission, or SEC, on February 22, 2012, and other documents filed with the SEC.

The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
2. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
3. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
4. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
5. Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
6. Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call
7. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
8. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
9. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
10. Syndax Pharmaceuticals Appoints Arlene Morris as CEO
11. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer health ... EmblemHealth , the New York -based ... RedBrick Compass health assessment, combined with the RedBrick Journeys ... EmblemHealth is among the first health plans in the ...
(Date:1/15/2014)... 15, 2014 More than 5 million ... 1 in 3 seniors will die with Alzheimer’s or ... jaw-dropping figures have shocked many Americans into looking for ... prevent these tragic age-related cognitive disorders. Jonathan Weisman, president ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched Sound ... Patients listen to sound therapy that is tailor-made for ... to months, their tinnitus volume decreases. , AudioNotch has previously ... Notched White Noise. Now, AudioNotch is pleased to announce to ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2DTS Improves Efficiency for Life Science Document Translations 2
... http://www.thirdbiotech.com ), a biotechnology incubator and life ... the ThirdBiotech Research,Group including a drug discovery ... of collaborative activities between researchers,and industry for ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070911/LATU119LOGO ), "Over ...
... 25 The U.S. Food and Drug,Administration ... Drugs,voted to recommend the approval of tolvaptan, ... treatment,for patients with hyponatremia., "Otsuka is ... the,potential approval of tolvaptan, an investigational selective,V2-vasopressin ...
... is,strengthening its customer-focused biomarker services portfolio to,pharmaceutical, ... Xie will lead those efforts as Battelle,s ... a suite of biomarker services, including biomarker,discovery, ... clients,better define molecular mechanisms of diseases, toxicity, ...
Cached Biology Technology:ThirdBiotech Launches Research Institute to Promote Formation and Growth of Arizona-Based Biotech Companies 2U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia 2Battelle Selects Xie to Develop Biomarker Services 2
(Date:4/18/2014)... PROVIDENCE, R.I. [Brown University] Asteroid and comet impacts ... animals on regional or even global scales. But new ... preserve the signatures of ancient life at the time ... Brown geologist Pete Schultz has found fragments of leaves ... a several ancient impacts in Argentina. The material could ...
(Date:4/17/2014)... trials to treat tuberculosis could be the basis for ... bacteria, fungal infections and parasites, yet evade resistance, according ... collaborators. , Led by U. of I. chemistry professor ... drug SQ109 attacks the tuberculosis bacterium, how the drug ... to malaria and how targeting multiple pathways reduces ...
(Date:4/17/2014)... April 17, 2014The development of stem cell therapies to ... to characterize stem cell populations based on cell surface ... a new marker that is highly expressed in a ... blood, which they describe in an article in ... Ann Liebert, Inc., publishers. The article is available free ...
Breaking Biology News(10 mins):Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3Multitarget TB drug could treat other diseases, evade resistance 2
... their native language of 1 and 0 absolutes but struggle ... While scientists are making slow, incremental progress in their quest ... body language, a more straightforward method of communication may help ... of researchers led by Charlie Kemp, director of the Center ...
... the equatorial Pacific long before Europeans arrived in the ... the way from modern-day Chile to western Mexico, according ... of Materials Science and Engineering. Details of ... years ago were reconstructed largely through the efforts of ...
... is a conspicuous and exaggerated display shaped by sexual ... attraction. At the level of the individual, song is ... Laiolo and colleagues at the Spanish Council of Research ... in north-eastern Spain and found an association between individual ...
Cached Biology News:Robot fetches objects with just a point and a click 2Robot fetches objects with just a point and a click 3Robot fetches objects with just a point and a click 4Floating a big idea: MIT demos ancient use of rafts to transport goods 2Floating a big idea: MIT demos ancient use of rafts to transport goods 3Floating a big idea: MIT demos ancient use of rafts to transport goods 4
... The University of New South Wales, Sydney, Australia ... Australia This is the Fourth Edition of this ... is a large format version (330 x ... 3rd edition. This product number includes the ...
For absolute protein quantification. 4 peptides in 5 vials x 2 nmol per peptide...
... The Jouan RC10 series of vacuum concentrators/centrifugal ... protection features allied to rapid and safe ... can be combined with oil-free or high ... and a wide selection of rotors (eliminating ...
Monoclonal mouse antibody for immunihistology, clone AD12, Isotype IgG 1, purified, specific for rat pyruvatekinase type L, no cross-reactivities with other pyruvate kinase isoenzymes have been obser...
Biology Products: